tiprankstipranks
Trending News
More News >
RxSight (RXST)
NASDAQ:RXST
US Market

RxSight (RXST) Stock Forecast & Price Target

Compare
240 Followers
See the Price Targets and Ratings of:

RXST Analyst Ratings

Hold
9Ratings
Hold
1 Buy
7 Hold
1 Sell
Based on 9 analysts giving stock ratings to
RxSight
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RXST Stock 12 Month Forecast

Average Price Target

$11.79
▲(48.30%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for RxSight in the last 3 months. The average price target is $11.79 with a high forecast of $22.00 and a low forecast of $9.00. The average price target represents a 48.30% change from the last price of $7.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","57":"$57","20.25":"$20.3","32.5":"$32.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,20.25,32.5,44.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,13.803076923076922,14.486153846153845,15.169230769230769,15.852307692307692,16.535384615384615,17.21846153846154,17.90153846153846,18.584615384615383,19.267692307692307,19.950769230769232,20.633846153846154,21.316923076923075,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,13.017692307692307,12.915384615384614,12.813076923076922,12.71076923076923,12.608461538461537,12.506153846153845,12.403846153846153,12.301538461538462,12.199230769230768,12.096923076923076,11.994615384615384,11.892307692307691,{"y":11.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.12,12.803076923076922,12.486153846153845,12.169230769230769,11.852307692307692,11.535384615384615,11.218461538461538,10.901538461538461,10.584615384615384,10.267692307692307,9.95076923076923,9.633846153846154,9.316923076923077,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$22.00Average Price Target$11.79Lowest Price Target$9.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RXST
TipRanks AITipRanks
Not Ranked
TipRanks
$7.5
Hold
-5.66%
Downside
Reiterated
07/10/25
The overall stock score reflects a mix of strong revenue growth and customer satisfaction, offset by significant operational and profitability challenges. Bearish technical signals and a negative valuation picture further contribute to the lower score.
Jefferies Analyst forecast on RXST
Young LiJefferies
Jefferies
$24$9
Hold
13.21%
Upside
Downgraded
07/10/25
RxSight downgraded to Hold from Buy at JefferiesRxSight downgraded to Hold from Buy at Jefferies
Oppenheimer Analyst forecast on RXST
Steven LichtmanOppenheimer
Oppenheimer
Hold
Downgraded
07/09/25
RxSight downgraded to Perform from Outperform at OppenheimerRxSight downgraded to Perform from Outperform at Oppenheimer
Piper Sandler Analyst forecast on RXST
Adam MaederPiper Sandler
Piper Sandler
$18$10
Hold
25.79%
Upside
Reiterated
07/09/25
RxSight price target lowered to $10 from $18 at Piper SandlerRxSight price target lowered to $10 from $18 at Piper Sandler
Wells Fargo Analyst forecast on RXST
Larry BiegelsenWells Fargo
Wells Fargo
$9
Hold
13.21%
Upside
Downgraded
07/09/25
Wells Fargo downgrades RxSight (RXST) to a Hold
Bank of America Securities Analyst forecast on RXST
Craig BijouBank of America Securities
Bank of America Securities
$18$9
Sell
13.21%
Upside
Reiterated
07/09/25
Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Gain Therapeutics (NASDAQ: GANX) and Edwards Lifesciences (NYSE: EW)
Needham
$22
Buy
176.73%
Upside
Reiterated
07/09/25
RxSight's Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
Stifel Nicolaus Analyst forecast on RXST
Thomas StephanStifel Nicolaus
Stifel Nicolaus
$17$9
Hold
13.21%
Upside
Reiterated
07/09/25
RxSight price target lowered to $9 from $17 at StifelRxSight price target lowered to $9 from $17 at Stifel
BTIG
Hold
Downgraded
07/09/25
RxSight downgraded to Neutral from Buy at BTIGRxSight downgraded to Neutral from Buy at BTIG
AI Firm
$15.5$14.5
Hold
82.39%
Upside
Reiterated
06/12/25
UBS
$45$16
Hold
101.26%
Upside
Downgraded
04/09/25
RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating
J.P. Morgan Analyst forecast on RXST
Robbie MarcusJ.P. Morgan
J.P. Morgan
$40$17
Sell
113.84%
Upside
Downgraded
04/03/25
RxSight downgraded to Underweight from Overweight at JPMorganRxSight downgraded to Underweight from Overweight at JPMorgan
Morgan Stanley Analyst forecast on RXST
Patrick WoodMorgan Stanley
Morgan Stanley
$42
Buy
428.30%
Upside
Reiterated
04/03/25
RxSight's Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RXST
TipRanks AITipRanks
Not Ranked
TipRanks
$7.5
Hold
-5.66%
Downside
Reiterated
07/10/25
The overall stock score reflects a mix of strong revenue growth and customer satisfaction, offset by significant operational and profitability challenges. Bearish technical signals and a negative valuation picture further contribute to the lower score.
Jefferies Analyst forecast on RXST
Young LiJefferies
Jefferies
$24$9
Hold
13.21%
Upside
Downgraded
07/10/25
RxSight downgraded to Hold from Buy at JefferiesRxSight downgraded to Hold from Buy at Jefferies
Oppenheimer Analyst forecast on RXST
Steven LichtmanOppenheimer
Oppenheimer
Hold
Downgraded
07/09/25
RxSight downgraded to Perform from Outperform at OppenheimerRxSight downgraded to Perform from Outperform at Oppenheimer
Piper Sandler Analyst forecast on RXST
Adam MaederPiper Sandler
Piper Sandler
$18$10
Hold
25.79%
Upside
Reiterated
07/09/25
RxSight price target lowered to $10 from $18 at Piper SandlerRxSight price target lowered to $10 from $18 at Piper Sandler
Wells Fargo Analyst forecast on RXST
Larry BiegelsenWells Fargo
Wells Fargo
$9
Hold
13.21%
Upside
Downgraded
07/09/25
Wells Fargo downgrades RxSight (RXST) to a Hold
Bank of America Securities Analyst forecast on RXST
Craig BijouBank of America Securities
Bank of America Securities
$18$9
Sell
13.21%
Upside
Reiterated
07/09/25
Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Gain Therapeutics (NASDAQ: GANX) and Edwards Lifesciences (NYSE: EW)
Needham
$22
Buy
176.73%
Upside
Reiterated
07/09/25
RxSight's Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
Stifel Nicolaus Analyst forecast on RXST
Thomas StephanStifel Nicolaus
Stifel Nicolaus
$17$9
Hold
13.21%
Upside
Reiterated
07/09/25
RxSight price target lowered to $9 from $17 at StifelRxSight price target lowered to $9 from $17 at Stifel
BTIG
Hold
Downgraded
07/09/25
RxSight downgraded to Neutral from Buy at BTIGRxSight downgraded to Neutral from Buy at BTIG
AI Firm
$15.5$14.5
Hold
82.39%
Upside
Reiterated
06/12/25
UBS
$45$16
Hold
101.26%
Upside
Downgraded
04/09/25
RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating
J.P. Morgan Analyst forecast on RXST
Robbie MarcusJ.P. Morgan
J.P. Morgan
$40$17
Sell
113.84%
Upside
Downgraded
04/03/25
RxSight downgraded to Underweight from Overweight at JPMorganRxSight downgraded to Underweight from Overweight at JPMorgan
Morgan Stanley Analyst forecast on RXST
Patrick WoodMorgan Stanley
Morgan Stanley
$42
Buy
428.30%
Upside
Reiterated
04/03/25
RxSight's Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RxSight

1 Month
xxx
Success Rate
14/25 ratings generated profit
56%
Average Return
+6.23%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +6.23% per trade.
3 Months
xxx
Success Rate
12/25 ratings generated profit
48%
Average Return
+8.10%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +8.10% per trade.
1 Year
Success Rate
13/25 ratings generated profit
52%
Average Return
+39.95%
reiterated a buy rating 2 days ago
Copying David Saxon's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of +39.95% per trade.
2 Years
xxx
Success Rate
8/25 ratings generated profit
32%
Average Return
+31.76%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 32.00% of your transactions generating a profit, with an average return of +31.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RXST Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
7
5
7
6
5
Buy
7
7
4
2
0
Hold
5
9
9
11
12
Sell
0
2
3
3
3
Strong Sell
0
0
0
0
0
total
19
23
23
22
20
In the current month, RXST has received 5 Buy Ratings, 12 Hold Ratings, and 3 Sell Ratings. RXST average Analyst price target in the past 3 months is 11.79.
Each month's total comprises the sum of three months' worth of ratings.

RXST Financial Forecast

RXST Earnings Forecast

Next quarter’s earnings estimate for RXST is -$0.24 with a range of -$0.33 to -$0.15. The previous quarter’s EPS was -$0.20. RXST beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.
Next quarter’s earnings estimate for RXST is -$0.24 with a range of -$0.33 to -$0.15. The previous quarter’s EPS was -$0.20. RXST beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.

RXST Sales Forecast

Next quarter’s sales forecast for RXST is $35.19M with a range of $33.60M to $39.00M. The previous quarter’s sales results were $37.90M. RXST beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.
Next quarter’s sales forecast for RXST is $35.19M with a range of $33.60M to $39.00M. The previous quarter’s sales results were $37.90M. RXST beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year RXST has Preformed in-line its overall industry.

RXST Stock Forecast FAQ

What is RXST’s average 12-month price target, according to analysts?
Based on analyst ratings, RxSight’s 12-month average price target is 11.79.
    What is RXST’s upside potential, based on the analysts’ average price target?
    RxSight has 48.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RXST a Buy, Sell or Hold?
          RxSight has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 1 sell ratings.
            What is RxSight’s price target?
            The average price target for RxSight is 11.79. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $22.00 ,the lowest forecast is $9.00. The average price target represents 48.30% Increase from the current price of $7.95.
              What do analysts say about RxSight?
              RxSight’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of RXST?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis